Measuring long‐term disease control in atopic dermatitis: a validation study of well controlled weeks by Langan, Sinéad M. et al.
Langan, Sinéad M. and Stuart, Beth and Bradshaw, 
Lucy and Schmitt, Jochen and Williams, Hywel C. and 
Thomas, Kim S. (2017) Measuring long term disease ‐
control in atopic dermatitis: a validation study of well 
controlled weeks. Journal of Allergy and Clinical 
Immunology . ISSN 1097-6825 (In Press) 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/40565/8/1-s2.0-S0091674917306772-main.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Measuring long-term disease control in patients
with atopic dermatitis: A validation study of well-
controlled weeksSinead M. Langan, PhD,a Beth Stuart, PhD,b Lucy Bradshaw, MSc,c Jochen Schmitt, MPH,d,e
Hywel C. Williams, PhD,d and Kim S. Thomas, PhDd London, Southampton, and Nottingham, United Kingdom, and Dresden,
GermanyBackground: Because atopic dermatitis (AD) is a relapsing
remitting disease, assessing long-term control is important.
Well-controlled weeks (WCWs) have been used to assess asthma
long-term control but have never been validated for AD.
Objectives: We sought to assess the feasibility, validity, and
interpretability of WCWs in patients with AD.
Methods: Three studies of patients with moderate-to-severe AD,
including 4 to 6 months of daily/weekly symptom and treatment
use data, were evaluated (study A, n 5 336; study B, n 5 60;
and study C, n 5 224). WCWs were defined by worsening
symptoms and increased medication use. Feasibility, construct
validity, and interpretability of WCWs were determined by
assessing missing data, association with validated AD outcomes,
and floor and ceiling effects. Analysis used linear and logistic
regression.
Results: WCWs were feasible to collect: 95.2% (study A) and
94.7% (study B) contributed data for at least half of the weekly
data points, and 93.2% and 88.7% contributed to all data points
up to 4 months. WCWs were significantly associated with
validated AD severity instruments, including patient-orientated
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http://dx.doi.org/10.1016/j.jaci.2017.02.043Severity Index, Three Item Severity Score, and Six Signs, Six
Areas Atopic Dermatitis Scale). The odds of experiencing a
WCW if AD severity was clear/mild was 5.8 (95% CI, 3.5-9.7),
1.9 (95% CI, 0.8-4.4), and 8.1 (95% CI, 4.5-14.6) in studies A, B,
and C, respectively. WCWs were associated with ceiling effects:
31.6% (study A) and 37.5% (study B) of participants had no
WCWs more than 90% of the time.
Conclusions: WCWs are valid and feasible for measuring long-
term control in AD trials. However, ceiling effects and burden of
data collection can limit use. (J Allergy Clin Immunol
2017;nnn:nnn-nnn.)
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Atopic dermatitis (AD; also known as atopic eczema or
eczema) is the most common inflammatory disease of childhood,
affecting 20% of children at some point in their lives and
approximately 3% of adults.1,2 It is characterized by a chronic re-
lapsing remitting disease course. Flares are a major component of
disease morbidity, with major effects on patients and their fam-
ilies.3 Capturing chronicity of disease and measures of longer-
term disease control is an important clinical outcome and is
becoming increasingly important with the drive for more prag-
matic, longer-term comparative effectiveness trials.4
Research in AD has been hampered by the use of a vast array of
outcome measures, the majority of which have not been
adequately validated.5 The Harmonising Outcome Measures in
Eczema (HOME) initiative (www.homeforeczema.org) is an in-
ternational collaborative effort comprising international stake-
holders, who are working together to establish consensus over a
core outcome set for AD research. Measuring long-term control
has been identified as a core outcome domain for clinical trials
in AD, but at present, there is no established and validated mea-
sure to do this.4,6
To address the lack of an accepted and validated way of
measuring long-term control in AD, our group previously
proposed a definition for well-controlled weeks (WCWs) based
on the literature in the field of asthma.7 The proposed definition
for aWCW is based on having 2 days or fewer with (1) symptoms
greater than a prespecified level and (2) escalation of treatment
required. HenceWCWs reflect a behavioral response to the wors-
ening of AD. WCWs are distinct from totally controlled weeks,
where no symptoms are observed during a week. Thus a WCW
is based on the concept that if the chronic disease is only associ-
ated with increased symptoms for 2 or fewer days that week, it is
relatively well controlled. Hence, if a study participant has fewer
WCWs, they have worse disease control, whereas those with
many WCWs have well-controlled disease. This definition of
WCWs has not previously been validated or evaluated in an AD1
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2 LANGAN ET ALAbbreviations usedAD: Atopic dermatitisCLOTHES: Clothing for the Relief of Eczema SymptomsEASI: Eczema Area and Severity IndexHOME: Harmonising Outcome Measures in EczemaPOEM: Patient Orientated Eczema MeasureSASSAD: Six Signs, Six Areas Atopic Dermatitis ScaleSWET: Softened Water Eczema TrialTIS: Three Item SeverityUK: United KingdomWCW: Well-controlled weekresearch setting.7,8 There is little clarity on howWCWs should be
measured or interpreted and how they relate to other validated
outcome measures for AD.
This article reports our experiences of using WCWs in 3
clinical studies (2 randomized controlled trials and 1 observa-
tional study): the Softened Water Eczema Trial (SWET), an
observational study of environmental triggers of disease flares in
childhood AD, and the Clothing for the Relief of Eczema
Symptoms (CLOTHES) trial.9-11 Study objectives were as fol-
lows: (1) to assess the feasibility of WCWs as a measure of
long-term AD control; (2) to explore the association between
WCWs and other validated AD outcome severity instruments (pa-
tient-reported severity and objective severity scales); and (3) to
evaluate the interpretability of WCWs by examining the floor
and ceiling effects and the relationship between WCWs and
eczema severity.
Floor and ceiling effects occur when a high proportion of study
participants experience the best or worst outcome for the majority
of the study period, respectively. In this study floor effects
occurred if a substantial proportion experienced a state of
WCWs for the majority of the study period. Conversely, ceiling
effects occurred when a substantial proportion of patients did not
achieve a WCW for the majority of the study period. Both floor
and ceiling effects are problematic because they hamper the
ability to distinguish at extremes of disease severity.METHODS
Ethics approval was not required for this study because it represents a
secondary analysis of existing data sets from previously conducted and
ethically approved studies.Data sources
Data from 3 United Kingdom (UK)–based studies (2 funded by the
National Institute for Health Research and 1 funded by the BUPA Foundation)
have been used to inform these analyses. The data sets include children with
moderate-to-severe AD who were recruited in both primary and secondary
care settings.
Study A: SWET.12 The SWET trial was a randomized controlled
trial of 4months’duration involving 336 childrenwithmoderate-to-severe AD
aged between 6 months and 16 years recruited between 2007 and 2009.
Children were recruited from 8 UK secondary care centers. Participants
received normal care plus an ion-exchange water softener or normal care
alone. Participants had clinic visits at baseline and 4, 12, and 16weeks. Data to
define WCWs were collected daily by using paper diaries. Validated AD
severity scales (the Patient-Orientated OutcomeMeasure [POEM], Six Signs,
Six Areas Atopic Dermatitis [SASSAD] scale, and Three Item Severity [TIS]
score) were completed during the clinic visits.13-15Study B: observational study to identify flare trig-
gers.9 This study was a 6-month prospective cohort study involving 60
children with moderate-to-severe AD assessing associations between envi-
ronmental exposures and disease flares in patients with AD between 2006 and
2007. Participants were aged up to 15 years and recruited from a single UK
center. Participants had clinic visits at baseline andmonthly for 6months. Data
to define WCWs were collected by using daily electronic diaries. Validated
AD severity scales (POEM and TIS) were completed during clinic visits.
Study C.11 The CLOTHES trial was a randomized controlled trial of
6 months’duration involving 300 childrenwith moderate-to-severe AD aged 1
to 15 years and recruited from 5 secondary care centers in the UK between
2013 and 2015. Participants received standard care plus silk therapeutic
clothing or standard care alone. Participants had clinic visits at baseline and 8,
16, and 24 weeks and completed weekly online questionnaires. WCWs were
not a specified outcome for the CLOTHES trial; however, data necessary to
define WCWs were available from weekly online questionnaires and clinic
visits, making inclusion in this validation study possible. Validated AD
severity scales (POEM, the Eczema Area and Severity Index [EASI], and TIS)
were completed during the clinic visits.Defining WCWs
We previously suggested that a WCW should be defined where treatment
escalation (stepping up of treatment) was used for only 2 or fewer days for that
week and where symptoms were increased to greater than a prespecified level
for 2 or fewer days during that week.8 Valid symptom assessment tools could
include either a patient global assessment or a self-reported bother/itch/scratch
score. The prespecified symptom level was proposed as being greater than 1 on
a 5-point Likert scale (0-4) or greater than 4 on an 11-point visual analog scale
(0-10).
We defined escalation of treatment as any additional treatment that had
been specified in the study protocol to deal with disease deterioration. In
some study designs, study treatment is used as an ‘‘as-required’’ treatment
in response to disease worsening, and therefore study treatment could be
considered treatment escalation. If a treatment was used for less than
2 days per week as proactive therapy for the prevention of flares, this was
not considered escalation of treatment.16 In those using low-potency ste-
roids, escalation could include increasing the steroid potency to moderate
or potent topical steroids. In those using potent steroids, stepping up to
superpotent topical steroids or using wet wraps could constitute an
escalation.
Table I9,11,13-15,17,18 provides a summary of how WCWs were defined in
each of the included studies. For studies A and B, escalation of treatment
was defined on an individual basis for each child by parents in conjunction
with study investigators at the start of the study. For study C, the number of
days of topical corticosteroids each week was used to define treatment
escalation.
WCWdatawere collected daily for studiesA andB andweekly for studyC.
For study C, data on the number of days that topical corticosteroids were used
were collected weekly, and global bother over the last week was collected
every 2 months. As such, WCWs in study C could only be calculated at 8, 16,
and 24 weeks, despite the availability of weekly treatment use data.
Details of other outcomes related to eczema severity collected in the
included studies are outlined in Table I.Evaluation of WCWs and hypotheses tested
Feasibility of collecting WCWs in clinical studies.
d Assessments were based on the amount of missing data for each of the
included data sets.
d WCWs were judged to be feasible to collect if more than 50% of partic-
ipants completed at least half of the daily/weekly questionnaires and if
more than 80% of participants were eligible for inclusion in the
repeated-measures analysis of WCWs (studies A and B only).
TABLE I. Data available from included studies
Data captured Study A17 Study B9 Study C11
How was moderate-to-severe
eczema defined?
SASSAD score >_10 >_3 Flare-ups in previous 6 mo Nottingham Eczema Severity Scale
(NESS) score of >_9
Definition of WCW used* WCW: <_2 d where stepping up of
treatment was required and <_2 d
with a bother score >4
WCW: <_2 d where stepping up of
treatment was required and <_2 d
with a bother score >4
WCW: <_2 d when topical
corticosteroids used and global
bother score <_4 for the week
Bother score (0-10): ‘‘How much
bother did your (your child’s)
eczema cause today?’’
Daily in paper diaries Daily in electronic diaries Bother over the last week assessed
at baseline and weeks 8, 16, and
24
Scratch score (0-10): ‘‘How much
did you (your child) scratch
today?’’
Daily Daily —
Treatment ‘‘stepped up’’
(individually defined at start of
study [yes/no])
Daily Daily —
Topical corticosteroid use (yes/no) Daily (yes/no) — Weekly (no. of days in last week)
Topical calcineurin inhibitor use
(yes/no)
Daily — Weekly (no. of days in last week)
POEM scores13 (range, 0-28) Baseline and weeks 4, 12, and 16 Baseline and weeks 4, 8, 12, 16,
20, and 24
Weekly
TIS scores15 (range, 0-9) Weeks 12 and 16 Baseline and weeks 4, 8, 12, 16,
20, and 24
Baseline and weeks 8, 16, and 24
SASSAD scores14 (range, 0-108) Weeks 12 and 16 — —
EASI scores18 (range, 0-72) — — Baseline and weeks 8, 16, and 24
*Higher WCWs represents better disease control.
Higher scores denote more severe disease.
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used AD outcome scales (construct validity).
d The degree to which WCWs relate to other validated outcome scales
(POEM, EASI, TIS, and SASSAD) was determined.
d We hypothesized that participants reporting a WCW would have lower
severity scores for AD symptoms (POEM) and AD signs (EASI, TIS,
and SASSAD) for that week.
Interpretability of WCWs.
d Assessment was done by examining the distribution of WCWs to look for
floor and ceiling effect and by assessing the odds of experiencing a WCW
according to eczema severity (using previously validated POEM bandings
for mild, moderate, and severe disease).19
d WCWs were assumed to have problematic ceiling effects if more than
15% of participants experienced no WCWs more than 90% of the time
or floor effects if more than 15% of participants experienced a WCW
more than 90% of the time.20
Statistical methods
Data management. The 3 data sets were analyzed individually to
explore the consistency and replication of our findings across different data
sets. Analysis of data set Awas considered exploratory, and analyses of data
sets B and C were considered confirmatory.
For study C, we included participants who had completed weekly
questionnaires (providing data on topical corticosteroid use and POEM
scores) up to 3 days before a clinic visit or 1 day after the clinic visit to
ensure that data were reported in the same time period as the disease severity
measures (EASI and TIS) and bother scores, which were captured during the
2-month clinic visits. This meant that 224 (75%) of the 300 trial participants
contributed to this validation study. As a result, study Cwas excluded from the
analysis of missing data (because all had available data to be included in the
study) and floor and ceiling effects (because only 3 data pointswere available).Feasibility: missing data. The quantity of missing data was
determined forWCWs in studies A andB. The following rules were developed
to handle missing data:
d If there were 3 days or more with either a bother score of greater than 4 or
where ‘‘stepping up’’ was required, then the week was not defined as a
WCW.
d If only 1 day had a bother score of greater than 4 and there is only 1
missing day, then the week was classed as a WCW; the same rules apply
for treatment escalation (stepping up of treatment).
Construct validity: association between WCWs and
validated scales. The strength and direction of association between
WCWs and other measures of disease severity (POEM, TIS, SASSAD, and
EASI scores) was assessed for weeks 4, 12, and 16 in study A; weeks 4, 8, 12,
16, 20, and 24 in study B; and weeks 8, 16, and 24 in study C.
Because data were captured at different time points in the 3 studies (Table
I), the primary analysis included participants with data for at least 2 of the time
points.
Given the repeated-measures nature of the study, data were analyzed by
using a mixed linear models in Stata software (version 14; StataCorp, College
Station. Tex). This allows participants who have missing data to contribute
information for any periods for which they have data at the same time point for
bothWCWs and the validated severity instrument; no assumptions were made
about missing values.
Interpretability. The proportion of the study period spent with a
WCWwas calculated for all participants who contributed data for at least 50%
of the study period to explorewhetherWCWswere subject to floor and ceiling
effects (studies A and B only).
Predefined categorical bands for POEM scores were used to evaluate
clinical interpretability: clear/mild (0-7), moderate (8-16), and severe/very
severe (17-28) AD.19 Participants needed to have data on WCWs and POEM
scores for at least 1 time point after baseline to contribute to the analysis. The
relationship between POEM severity and WCWs was determined by using
TABLE II. Baseline characteristics of the subjects included in each study
Study A Study B Study C
No. of participants 325 59* 224
Age, no. (%)
Mean age (y [SD]) 5.40 (4.11) 7.3 (4.8) 5.1 (3.6)
Less than 3 y 94 (29) 14 (23) 73 (33)
3-6 y 118 (36) 13 (22) 78 (35)
>_7 y 113 (35) 33 (55) 73 (33)
Sex, no. (%)
Male 185 (57) 32 (53) 128 (57)
Female 140 (43) 28 (47) 96 (43)
Ethnicity, no. (%)
White 253 (78) 38 (63) 183 (82)
Asian 29 (9) 14 (23) 10 (4)
Black 10 (3) 4 (7) 4 (2)
Mixed 19 (6) 4 (7) 18 (8)
Other 12 (4) 0 9 (4)
Not stated/unknown 2 (1) 0 0
AD severity (POEM)13
Mean (SD) 16.7 (5.81) 12.4 (6.4) 17.0 (5.2)
AD severity: Clinical signs
SASSAD score, no. (%)14
Mean (SD) 25.5 (13.40) NA NA
10-19 138 (43) NA NA
>20 186 (57) NA NA
EASI score18
Mean (SD) NA NA 10.5 (9.2)
TIS score15
Mean (SD) 3.9 (1.8) 3.1 (1.5) 4.9 (1.8)
NA, Not applicable.
*One participant was unable to be included because he or she contributed no data.
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group.
Power. No formal sample size estimation was conducted because the
sample size for this study was pragmatic based on data availability. A sample
size of greater than 100 participants per analysis has been recommended as
sufficient for validation studies.21RESULTS
Overall, 608 participants contributed to the analyses (study A,
n 5 325; study B, n 5 59; and study C, n 5 224). Baseline
characteristics of included participants are summarized and
demonstrate similar baseline characteristics, although study B is
significantly smaller than studies A and C (Table II).Objective 1: Feasibility of WCWs as a measure of
long-term control
Testing the hypothesis that more than 50% of participants
would complete at least half of the daily/weekly questionnaires
during the study period, we found high completion rates for
WCWs. In study A 320 (95.2%) of 336 participants contributed
WCW data for more than half of the 16-week study period, and
325 (97%) of 336 had at least 1WCWafter baseline. In study B 56
(94.7%) of 59 contributedWCWdata for more than half of the 24-
week study period. In study A sufficient data were available to
calculate aWCW 94.5% of the time at 3 months and 93.2% of the
time at 4 months. For study B, the data were available 91.9% of
the time at 3 months and 88.7% of the time at 4 months.
Testing the hypothesis that at least 80% of participants would
be eligible for inclusion in a repeated-measures analysis(assuming that participants could be included if they contributed
at least 1 data point for WCWs after baseline), most participants
were able to be included (97% in study A and 100% in study B).Objective 2: Association between WCWs and other
commonly used AD outcome scales
The hypothesis that participants reporting a WCWwould have
lower AD severity scores for the corresponding week was
supported. For all 3 studies, POEM and TIS scores were lower
in subjects with a WCW compared with those who did not have a
WCW (P < .05 for study B and P < .01 for studies A and B,
Table III). In studies A and C, in which data for SASSAD and
EASI scores were available, a similar pattern was observed
(Table III).Objective 3: Interpretability of WCWs by examining
the floor and ceiling effect and the relationship
between WCWs and eczema severity
The proportion of time spent with a WCW during the study
period is shown (Fig 1) and suggests potentially problematic ceil-
ing effects in that more than 15% of the participants spent more
than 90% of the time without a WCW (Fig 1); hence a substantial
proportion of subjects had poor control of their eczema
throughout the study period.
In study A 32 (10%) participants spent more than 90% of the
study with a WCW, and 101 (31.6%) spent more than 90% of the
study period without a WCW. In study B 2 (3.4%) participants
spent more than 90% of the study period with a WCW, and 21
TABLE III. Strength and direction of the association between WCWs and other AD outcome measures (construct validity)
Study A (n 5 325) Study B (n 5 59) Study C (n 5 224)
Mean (SD)
score for those
with a WCW
Mean (SD)
score in those
without a
WCW
Difference in score for
those with a
WCW compared
with those
without (95% CI)
Mean (SD)
score for those
with a WCW
Mean (SD)
score in those
without a
WCW
Difference in score
for those with a
WCW compared
with those without
(95% CI)
Mean (SD)
score for
those with
a WCW
Mean (SD)
score in
those without
a WCW
Difference in score for
those with a WCW
compared with those
without (95% CI)
POEM
score
(range,
0-28)*
9.20 (5.75) 14.68 (6.37) 24.28 (25.08 to 23.48) 9.17 (5.92) 13.82 (6.49) 21.92 (23.26 to 20.58) 6.83 (5.34) 14.25 (6.29) 25.98 (27.36 to 24.59)
TIS score
(range,
0-9)*
2.24 (1.61) 2.98 (1.89) 20.49 (20.72 to 20.27) 2.15 (1.48) 3.04 (1.97) 20.40 (20.76 to 20.03) 2.83 (1.55) 4.23 (2.00) 21.20 (21.66 to 20.74)
SASSAD
score
(range,
0-108)*
15.42 (9.98) 23.65 (13.83) 24.34 (25.61 to 23.07) NA NA NA NA
EASI score
(range,
0-72)*
NA NA NA NA 3.51 (5.13) 9.19 (10.19) 23.24 (25.16 to 21.31)
NA, Not applicable.
*High scores denote more severe disease.
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without a WCW.
The association between WCW scores and AD severity (based
on validated POEM bandings) suggests that WCWs are a useful
reflection of AD severity. Compared with those with moderate
POEM scores, patients with mild or clear AD were more likely to
have had a WCW, whereas those with severe or very severe AD
were much less likely to have had aWCW (Table IV). For studies
A and C these differences were statistically significant, whereas
for study B, the relationship was in the same direction but not sta-
tistically significant, although this might reflect the smaller sam-
ple size of this study.DISCUSSION
Main findings
In this study we have shown that WCWs as defined in the 3
included data sets show good feasibility and construct validity but
might be limited by ceiling effects in patients with moderate-to-
severe disease. WCWs appear to correlate well with other
measures of AD severity, including both POEM and objective
outcome instruments capturing AD signs (TIS, EASI, and
SASSAD).
Assessment of feasibility is particularly important because
measures that are unduly time consuming to collect and analyze
or are prone to missing values are unlikely to be recommended for
a core outcome instrument.22 Measuring long-term control on a
daily or weekly basis to define WCWs (by using a combination
of symptoms and the need to use AD medications) is a novel
approach to determining disease control but is potentially burden-
some to both patients and researchers. However, the high comple-
tion rates in the included studies would suggest acceptability to
patients. It is possible that with increasing use of online tools
andmobile phone apps, the technological difficulties of collecting
daily or weekly data can be overcome.
Responsiveness is an important criterion for quality assessment
of outcome instruments, which has not yet been evaluated. As a
binary measure, it might be difficult for a WCW to adequately
capture change over time, and the observed ceiling effects couldmake it difficult to demonstrate meaningful change.20 Further
work to evaluate responsiveness of WCWs is required.Relevance to other studies
It is not yet clear what measure to use and how frequently AD
should be assessed to estimate long-term control within the context
of a randomized controlled trial, a topic that has been identified as a
key priority for future research by a multidisciplinary stakeholder
group.23 The majority of previous studies have used either patient-
reported or objective severity scores assessed 1 to 2 months apart,
usually during clinic visits.5,22 The optimum frequency of data
collection to capture the chronic relapsing nature of AD is not
yet known, although it has been reported that assessment of AD
severity twice a week provides additional information compared
with AD severity collected at 2 months.24 The concept of WCWs
has been developed specifically to assess the nature of long-term
control of eczema. It is a complexmeasure capturing both the effect
of eczema symptoms and the need for treatment escalation.
Although capturing the multiple dimensions of eczema control is
attractive, usingWCWs increases the questionnaire burden on par-
ticipants and investigators.
Previous work looking at the validation of flare outcomes has
suggested that use of topical corticosteroids, calcineurin in-
hibitors, or both is as sensitive for capturing AD flares as the
concept of treatment escalation.25 The current study supports this
finding because WCWs defined by use of topical corticosteroids/
calcineurin inhibitors (in study C) demonstrated similar levels of
association with validated scales as those seen in the 2 studies that
used escalation of treatment in defining WCWs.
Strengths and limitations
This study used existing data sets that had been collected
originally for another purpose. As a result, some of the analyses
were limited by the available data. In the case of study C, the
definition of WCWs was post hoc and might have influenced the
analyses. Nevertheless, we explored the performance of WCWs
in the 3 data sets separately and tested predefined hypotheses.
We were able to replicate findings in the separate data sets,
lending support to the validity of these findings. It is possible
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FIG 1. Proportion of the study period spent without a WCW to determine whether there are relevant floor or
ceiling effects: A, study A; B, study B.
TABLE IV. Relationship between WCWs and AD severity based on POEM scores as a categorical variable (clear/mild and severe/
very severe categories collapsed together)
Categories of
POEM scores
Study A: odds
ratio for a WCW (95% CI)
Study B: odds ratio for
a WCW (95% CI)
Study C: odds ratio
for a WCW (95% CI)
Mild (POEM score, 0-7) 5.78 (3.46-9.67) 1.91 (0.82-4.45) 8.08 (4.48-14.59)
Moderate (POEM score, 8-16; reference category) 1.00 1.00 1.00
Severe (POEM score, 17-28) 0.30 (0.17-0.52) 0.57 (0.21-1.52) 0.44 (0.17-1.14)
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tween the included studies because all 3 were recruited in Not-
tingham, and there was some additional overlap between
studies A and C in the recruiting sites. However, the studies
were conducted at different periods from 2006 to 2015, and there-
fore any overlap is likely to be small.
It is currently unclear what proportion of time in aWCWwould
represent ‘‘good control’’ (which might vary by disease severity),
and further work is required to determinewhether definitions used
to define WCWs can be consistently applied to different studiesand populations. Our findings were remarkably consistent across
the 3 included studies, but these studies were all conducted in
children with moderate-to-severe disease and with participants
who were predominantly recruited in secondary care.Clinical and research implications
Understanding how to characterize and measure long-term
control is a key research priority for the HOME initiative,6 and
consensus discussions will be taking place at the next HOME
J ALLERGY CLIN IMMUNOL
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LANGAN ET AL 7meeting in June 2017 (www.homeforeczema.org). WCWs appear
to fulfil many of the criteria for consideration as an instrument for
measuring long-term control, but this assessment has limitations
that require further assessment.
Key messages
d WCWs are a composite measure of treatment use and
symptoms that have been proposed as a measure of
long-term AD control.
d WCWs appear to be closely related to other measures of
AD severity, indicating construct validity.
d Capturing data for WCWs can be time consuming, but
the limited missing data support acceptability to patients.
d Ceiling effects can be problematic in patients with
moderate-to-severe disease and might limit the ability to
detect change if participants experience few WCWs dur-
ing follow-up.
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